EYPT News and Press, EyePoint Pharmaceuticals Inc. From 02/21/24

2024-02-21 08:36:08 ET Summary EyePoint's EYP-1901 shows promising results in a Phase 2 trial for multiple eye conditions, potentially becoming the standard of care. The company has a strong drug delivery platform with Durasert and has sold off its profitable YUTIQ business. E...

2024-02-20 13:50:53 ET Summary EyePoint Pharmaceuticals' EYP-1901 drug for wet AMD showed positive results in Phase 2 clinical trials, potentially offering a lower-cost and more effective treatment option. The company's proprietary Durasert E technology delivers drugs directly to ...

2024-02-19 20:42:02 ET Summary Age-related macular degeneration (AMD) is a leading cause of vision loss and blindness, with wet AMD being a more severe form. Current treatment for wet AMD involves frequent anti-VEGF injections, but there is a need for therapies with less frequent ...

2024-02-17 00:40:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Financial markets are driven by cycles, and each cycle is accompanied by uptrends and downtrends. In the uptrends, those who have been previously positioned in companies with growth potential, ...

2024-02-09 06:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Subgroup analyses underscore favorable clinical profile and durability of EYP-1901 Presentations highlight previously reported positive Phase 2 DAVIO 2 topline results showing all primary and secondary endpoints were met Results presented today at the Angiogenesis, Exudation, and ...

WATERTOWN, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced that George Elston, Executive Vice President and Ch...

2024-01-22 17:36:05 ET More on EyePoint Pharmaceuticals EyePoint Pharmaceuticals Soaring On Wet AMD Study Results: Durasert Looks Real Deal Shorting EyePoint Pharmaceuticals Ahead Of Davio-2 Wet-AMD Data: Potential 78% Gain Countdown To Clarity: EyePoint's December D...

2024-01-18 16:55:37 ET Gainers: Ventyx Biosciences ( VTYX ) +6% . EyePoint Pharmaceuticals ( EYPT ) +3% . HashiCorp ( HCP ) +3% . Nubia Brand International  ( NUBI ) +2% . Microvision ( MVIS ) +2% . Losers: Spectaire...

2024-01-17 06:00:39 ET More on EyePoint Pharmaceuticals EyePoint Pharmaceuticals Soaring On Wet AMD Study Results: Durasert Looks Real Deal Countdown To Clarity: EyePoint's December Data Delivery EyePoint commences $175M stock offering to advance wet AMD therapy into...